Abstract
Introduction: Relapse rates in individuals with alcohol use disorder (AUD) are particularly high following inpatient treatment. Innovative strategies should specifically target the transitional gap between completion of inpatient treatment and uptake of standard continuing care. This study aimed to determine whether Appstinence, a digital approach that combines a smartphone app intervention with adjunct telephone coaching, more markedly reduces the risk of relapse for 6 months after inpatient AUD treatment in comparison to a control group with access to standard continuing care. Methods: In this multicenter clinical trial, 356 participants were randomized to the intervention (n = 175) or control group (n = 181). Eligibility criteria included diagnosis of AUD, smartphone access, no acute suicidality, and no language or neurocognitive impairments. The primary outcome was risk of relapse within 6 months after randomization, as assessed with the Timeline-Follow-Back method. Secondary outcomes included uptake of standard continuing care, hazardous alcohol consumption, craving, depression and anxiety symptom severity, and well-being. Results: The intervention reduced the risk of relapse within 6 months as indicated by a log-rank test (HR: 0.72, 95% CI: 0.53–0.98, p = 0.04) and Cox regression adjusted for baseline characteristics (HR: 0.67, 95% CI: 0.48–0.92, p = 0.01). This effect increased when participants fully adhered to the intervention protocol (log-rank test: HR: 0.61, 95% CI: 0.39–0.94, p = 0.02). No significant differences were observed in secondary outcomes. Conclusion: Our findings provide supportive evidence for digital AUD transition treatment. Specifically, we found that, in comparison with access standard continuing care, the novel intervention more effectively reduced risk of relapse within 6 months following inpatient treatment.
Journal Section:
Innovations
References
1.
Schoepf
D
, Heun
R
. Alcohol dependence and physical comorbidity: increased prevalence but reduced relevance of individual comorbidities for hospital-based mortality during a 12.5-year observation period in general hospital admissions in urban North-West England
. Eur Psychiatry
. 2015
;30
(4
):459
–68
. 2.
Atzendorf
J
, Rauschert
C
, Seitz
NN
, Lochbühler
K
, Kraus
L
. The use of alcohol, tobacco, illegal drugs and medicines: an estimate of consumption and substance-related disorders in Germany
. Dtsch Arztebl Int
. 2019
;116
(35–36
):577
–84
. 3.
Gabriels
CM
, Macharia
M
, Weich
L
. Psychiatric comorbidity and quality of life in South African alcohol use disorder patients
. Qual Life Res
. 2018
;27
(11
):2975
–81
. 4.
Rehm
J
, Shield
KD
. Global burden of alcohol use disorders and alcohol liver disease
. Biomedicines
. 2019
;7
(4
):99
. 5.
Barbosa
C
, Bray
JW
, Dowd
WN
, Barnosky
A
, Wittenberg
E
. SF-6D utility scores for alcohol use disorder status and alcohol consumption risk levels in the US population
. Addiction
. 2021
;116
(5
):1034
–42
. 6.
Castillo-Carniglia
A
, Keyes
KM
, Hasin
DS
, Cerdá
M
. Psychiatric comorbidities in alcohol use disorder
. Lancet Psychiatry
. 2019
;6
(12
):1068
–80
. 7.
Ugochukwu
C
, Bagot
KS
, Delaloye
S
, Pi
S
, Vien
L
, Garvey
T
, et al. The importance of quality of life in patients with alcohol abuse and dependence
. Harv Rev Psychiatry
. 2013
;21
(1
):1
–17
. 8.
Roerecke
M
, Rehm
J
. Cause-specific mortality risk in alcohol use disorder treatment patients: a systematic review and meta-analysis
. Int J Epidemiol
. 2014
;43
(3
):906
–19
. 9.
Rehm
J
, Gmel
G
, Sempos
CT
, Trevisan
M
. Alcohol-related morbidity and mortality
. Alcohol Res Health
. 2003
;27
(1
):39
–51
.10.
McKay
JR
, Hiller-Sturmhofel
S
. Treating alcoholism as a chronic disease: approaches to long-term continuing care
. Alcohol Res Health
. 2011
;33
(4
):356
–70
.11.
Nguyen
LC
, Durazzo
TC
, Dwyer
CL
, Rauch
AA
, Humphreys
K
, Williams
LM
, et al. Predicting relapse after alcohol use disorder treatment in a high-risk cohort: the roles of anhedonia and smoking
. J Psychiatr Res
. 2020
;126
:1
–7
. 12.
Moos
RH
, Moos
BS
. Rates and predictors of relapse after natural and treated remission from alcohol use disorders
. Addiction
. 2006
;101
(2
):212
–22
. 13.
Mohapatra
S
, Patra
J
, Popova
S
, Duhig
A
, Rehm
J
. Social cost of heavy drinking and alcohol dependence in high-income countries
. Int J Public Health
. 2010
;55
(3
):149
–57
. 14.
Trautmann
S
, Rehm
J
, Wittchen
HU
. The economic costs of mental disorders: do our societies react appropriately to the burden of mental disorders
. EMBO Rep
. 2016
;17
(9
):1245
–9
. 15.
Rehm
J
, Mathers
C
, Popova
S
, Thavorncharoensap
M
, Teerawattananon
Y
, Patra
J
. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders
. Lancet
. 2009
;373
(9682
):2223
–33
. 16.
Batra
A
, Müller
CA
, Mann
K
, Heinz
A
. Alcohol dependence and harmful use of alcohol diagnosis and treatment options
. Deutsches Arzteblatt Int
. 2016
;113
(17
):301
–U40
.17.
Witkiewitz
K
, Litten
RZ
, Leggio
L
. Advances in the science and treatment of alcohol use disorder
. Sci Adv
. 2019
;5
(9
):eaax4043
. 18.
Buchholz
A
, Rosahl
A
, Spies
M
, Silkens
A
, Scherbaum
N
, Reimer
J
, et al. Referral to subsequent addiction treatment after inpatient qualified alcohol detoxification A nationwide online survey
. Suchttherapie
. 2019
;20
(04
):212
–9
. 19.
Mojtabai
R
, Olfson
M
, Sampson
NA
, Jin
R
, Druss
B
, Wang
PS
, et al. Barriers to mental health treatment: results from the national comorbidity survey replication
. Psychol Med
. 2011
;41
(8
):1751
–61
. 20.
Kohn
R
, Saxena
S
, Levav
I
, Saraceno
B
. The treatment gap in mental health care
. Bull World Health Organ
. 2004
;82
(11
):858
–66
.21.
Gulliver
A
, Griffiths
KM
, Christensen
H
. Perceived barriers and facilitators to mental health help-seeking in young people: a systematic review
. BMC Psychiatry
. 2010
;10
:113
. 22.
Mack
S
, Jacobi
F
, Gerschler
A
, Strehle
J
, Höfler
M
, Busch
MA
, et al. Self-reported utilization of mental health services in the adult German population--evidence for unmet needs? Results of the DEGS1-Mental Health Module (DEGS1-MH)
. Int J Methods Psychiatr Res
. 2014
;23
(3
):289
–303
. 23.
Kiefer
F
, Batra
A
, Petersen
KU
, Ardern
IS
, Tananska
D
, Bischof
G
, et al. German guidelines on screening, diagnosis, and treatment of alcohol use disorders: update 2021
. Eur Addict Res
. 2022
;28
(4
):309
–22
. 24.
McKay
JR
. Impact of continuing care on recovery from substance use disorder
. Alcohol Res
. 2021
;41
(1
):01
. 25.
Ramadas
E
, de Lima
MP
, Caetano
T
, Lopes
J
, Dixe
M
. Effectiveness of smartphone interventions as continuing care for substance use disorders: a systematic review
. Acta Psychol
. 2023
;235
:103898
. 26.
Gustafson
DH
, McTavish
FM
, Chih
MY
, Atwood
AK
, Johnson
RA
, Boyle
MG
, et al. A smartphone application to support recovery from alcoholism: a randomized clinical trial
. JAMA Psychiatry
. 2014
;71
(5
):566
–72
. 27.
McKay
JR
, Gustafson
DH
, Ivey
M
, Pe-Romashko
K
, Curtis
B
, Thomas
T
, et al. Efficacy and comparative effectiveness of telephone and smartphone remote continuing care interventions for alcohol use disorder: a randomized controlled trial
. Addiction
. 2022
;117
(5
):1326
–37
. 28.
Hämäläinen
MD
, Zetterström
A
, Winkvist
M
, Söderquist
M
, Öhagen
P
, Andersson
K
, et al. Breathalyser-based eHealth data suggest that self-reporting of abstinence is a poor outcome measure for alcohol use disorder clinical trials
. Alcohol Alcohol
. 2020
;55
(3
):237
–45
. 29.
Mellentin
AI
, Nielsen
B
, Nielsen
AS
, Yu
F
, Mejldal
A
, Nielsen
DG
, et al. A mobile phone app featuring cue exposure therapy as aftercare for alcohol use disorders: an investigator-blinded randomized controlled trial
. JMIR Mhealth Uhealth
. 2019
;7
(8
):e13793
. 30.
You
CW
, Chen
YC
, Chen
CH
, Lee
CH
, Kuo
PH
, Huang
MC
, et al. Smartphone-based support system (SoberDiary) coupled with a Bluetooth breathalyser for treatment-seeking alcohol-dependent patients
. Addict Behav
. 2017
;65
:174
–8
. 31.
Farren
C
, Farrell
A
, Hagerty
A
, McHugh
C
. A 6-month randomized trial of a smartphone application, UControlDrink, in aiding recovery in alcohol use disorder
. Eur Addict Res
. 2022
;28
(2
):122
–33
. 32.
Saur
S
, Weisel
KK
, Lang
C
, Fuhrmann
LM
, Steins-Loeber
S
, Enewoldsen
N
, et al. App-based maintenance treatment for alcohol use disorder after acute inpatient treatment: study protocol for a multicentre randomized controlled trial
. Internet Interv
. 2022
;28
:100517
. 33.
Carroll
KM
, Kiluk
BD
. Cognitive behavioral interventions for alcohol and drug use disorders: through the stage model and back again
. Psychol Addict Behav
. 2017
;31
(8
):847
–61
. 34.
McHugh
RK
, Hearon
BA
, Otto
MW
. Cognitive behavioral therapy for substance use disorders
. Psychiatr Clin North Am
. 2010
;33
(3
):511
–25
. 35.
Ray
LA
, Meredith
LR
, Kiluk
BD
, Walthers
J
, Carroll
KM
, Magill
M
. Combined pharmacotherapy and cognitive behavioral therapy for adults with alcohol or substance use disorders: a systematic review and meta-analysis
. JAMA Netw Open
. 2020
;3
(6
):e208279
. 36.
Magill
M
, Ray
L
, Kiluk
B
, Hoadley
A
, Bernstein
M
, Tonigan
JS
, et al. A meta-analysis of cognitive-behavioral therapy for alcohol or other drug use disorders: treatment efficacy by contrast condition
. J Consult Clin Psychol
. 2019
;87
(12
):1093
–105
. 37.
Smedslund
G
, Berg
RC
, Hammerstrøm
KT
, Steiro
A
, Leiknes
KA
, Dahl
HM
, et al. Motivational interviewing for substance abuse
. Cochrane Database Syst Rev
. 2011
;2011
(5
):CD008063
. 38.
Morgenstern
J
, Kuerbis
A
, Houser
J
, Levak
S
, Amrhein
P
, Shao
S
, et al. Dismantling motivational interviewing: effects on initiation of behavior change among problem drinkers seeking treatment
. Psychol Addict Behav
. 2017
;31
(7
):751
–62
. 39.
Wiers
RW
, Eberl
C
, Rinck
M
, Becker
ES
, Lindenmeyer
J
. Retraining automatic action tendencies changes alcoholic patients’ approach bias for alcohol and improves treatment outcome
. Psychol Sci
. 2011
;22
(4
):490
–7
. 40.
Sobell
LC
, Sobell
MB
. Timeline follow-back: a technique for assessing self-reported alcohol consumption
. In: Litten
RZ
, Allen
JP
, editors. Measuring alcohol consumption: psychosocial and biochemical methods
. New Jersey
: Humana Press/Springer Nature
; 1992
. p. 41
–72
.41.
Saunders
JB
, Aasland
OG
, Babor
TF
, de la Fuente
JR
, Grant
M
. Development of the alcohol use disorders identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption--II
. Addiction
. 1993
;88
(6
):791
–804
. 42.
Meneses-Gaya
C
, Zuardi
AW
, Loureiro
SR
, Hallak
JE
, Trzesniak
C
, de Azevedo Marques
JM
, et al. Is the full version of the AUDIT really necessary? Study of the validity and internal construct of its abbreviated versions
. Alcohol Clin Exp Res
. 2010
;34
(8
):1417
–24
. 43.
Mann
K
, Ackermann
K
. The OCDS-G: psychometric characteristics of the German version of the obsessive compulsive drinking scale
. Sucht
. 2000
;46
(2
):90
–100
. 44.
de Wildt
WA
, Lehert
P
, Schippers
GM
, Nakovics
H
, Mann
K
, van den Brink
W
. Investigating the structure of craving using structural equation modeling in analysis of the obsessive-compulsive drinking scale: a multinational study
. Alcohol Clin Exp Res
. 2005
;29
(4
):509
–16
. 45.
Kroenke
K
, Spitzer
RL
, Williams
JB
. The PHQ-9: validity of a brief depression severity measure
. J Gen Intern Med
. 2001
;16
(9
):606
–13
. 46.
Gräfe
K
, Zipfel
S
, Herzog
W
, Löwe
B
. Screening for psychiatric disorders with the Patient Health Questionnaire (PHQ). Results from the German validation study
. Diagnostica
. 2004
;50
(4
):171
–81
. 47.
Spitzer
RL
, Kroenke
K
, Williams
JB
, Löwe
B
. A brief measure for assessing generalized anxiety disorder: the GAD-7
. Arch Intern Med
. 2006
;166
(10
):1092
–7
. 48.
Löwe
B
, Decker
O
, Müller
S
, Brähler
E
, Schellberg
D
, Herzog
W
, et al. Validation and standardization of the generalized anxiety disorder screener (GAD-7) in the general population
. Med Care
. 2008
;46
(3
):266
–74
. 49.
Brähler
E
, Mühlan
H
, Albani
C
, Schmidt
S
. Teststatistische Prüfung und Normierung der deutschen Versionen des EUROHIS-QOL Lebensqualität-Index und des WHO-5 Wohlbefindens-Index
. Diagnostica
. 2007
;53
(2
):83
–96
. 50.
Czapla
M
, Simon
JJ
, Richter
B
, Kluge
M
, Friederich
HC
, Herpertz
S
, et al. The impact of cognitive impairment and impulsivity on relapse of alcohol-dependent patients: implications for psychotherapeutic treatment
. Addict Biol
. 2016
;21
(4
):873
–84
. 51.
Loeber
S
, Croissant
B
, Heinz
A
, Mann
K
, Flor
H
. Cue exposure in the treatment of alcohol dependence: effects on drinking outcome, craving and self-efficacy
. Br J Clin Psychol
. 2006
;45
(Pt 4
):515
–29
. 52.
Linardon
J
, Cuijpers
P
, Carlbring
P
, Messer
M
, Fuller-Tyszkiewicz
M
. The efficacy of app-supported smartphone interventions for mental health problems: a meta-analysis of randomized controlled trials
. World Psychiatry
. 2019
;18
(3
):325
–36
. 53.
Donkin
L
, Christensen
H
, Naismith
SL
, Neal
B
, Hickie
IB
, Glozier
N
. A systematic review of the impact of adherence on the effectiveness of e-therapies
. J Med Internet Res
. 2011
;13
(3
):e52
. 54.
Little
RJ
, D'Agostino
R
, Cohen
ML
, Dickersin
K
, Emerson
SS
, Farrar
JT
, et al. The prevention and treatment of missing data in clinical trials
. N Engl J Med
. 2012
;367
(14
):1355
–60
. 55.
Andresen-Streichert
H
, Müller
A
, Glahn
A
, Skopp
G
, Sterneck
M
. Alcohol biomarkers in clinical and forensic contexts
. Dtsch Arztebl Int
. 2018
;115
(18
):309
–15
. 56.
Grüner Nielsen
D
, Andersen
K
, Søgaard Nielsen
A
, Juhl
C
, Mellentin
A
. Consistency between self-reported alcohol consumption and biological markers among patients with alcohol use disorder - a systematic review
. Neurosci Biobehav Rev
. 2021
;124
:370
–85
. 57.
Larimer
ME
, Palmer
RS
, Marlatt
GA
. Relapse prevention. An overview of Marlatt's cognitive-behavioral model
. Alcohol Res Health
. 1999
;23
(2
):151
–60
.© 2025 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
You do not currently have access to this content.
